Author:
Zhao Wei,Xiang Zheng,Zeng Weilin,Qin Yucheng,Pan Maohua,Wu Yanrui,Duan Mengxi,Mou Ye,Liang Tao,Zhang Yanmei,Liu Cheng,Tang Xiuya,Huang Yaming,Yang Gongchao,Cui Liwang,Yang Zhaoqing
Abstract
ABSTRACTPlasmodium falciparumacetyl-CoA synthetase (PfACAS) protein is an important source of acetyl-CoA. We detected the mutations S868G and V949I in PfACAS by whole-genome sequencing analysis in some recrudescent parasites after antimalarial treatment with artesunate and dihydroartemisinin-piperaquine, suggesting that they may confer drug resistance. Using CRISPR/Cas9 technology, we engineered parasite lines carrying the PfACAS S868G and V949I mutations in two genetic backgrounds and evaluated their susceptibility to antimalarial drugs in vitro. The results demonstrated that PfACAS S868G and V949I mutations alone or in combination were not enough to provide resistance to antimalarial drugs.
Publisher
Cold Spring Harbor Laboratory